0 155

Cited 0 times in

Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy

DC Field Value Language
dc.contributor.author김승일-
dc.contributor.author김지예-
dc.contributor.author박병우-
dc.contributor.author박세호-
dc.contributor.author박정민-
dc.contributor.author박형석-
dc.contributor.author안지현-
dc.contributor.author고지언-
dc.date.accessioned2024-01-03T00:13:58Z-
dc.date.available2024-01-03T00:13:58Z-
dc.date.issued2023-11-
dc.identifier.issn1068-9265-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/197200-
dc.description.abstractPurpose: Few studies have reported on patient prognosis according to residual cancer burden after neoadjuvant chemotherapy (NAC). Herein, we evaluated the survival of patients based on residual disease after NAC to identify subpopulations with distinct prognoses. Methods: We retrospectively reviewed 728 patients treated with NAC from 2010 to 2017. Patients were divided into four subgroups depending on post-surgical residual disease according to the staging system: pathological complete response (pCR) (ypT0/TisN0), minimal residual disease (MRD) (ypT1mi/T1aN0 or ypT0/Tis ypN0i+/N1mic), node-only pCR (≥ ypT1b ypN0), and breast-only pCR (ypT0/Tis ≥ ypN1a). Clinicopathological characteristics and survival outcomes were analyzed by adjusting for factors affecting survival. Results: Overall, 50.4% (n = 367) of patients achieved pCR, with the MRD group accounting for 16.5% (n = 120). Although age and clinical stage were not different among the study groups, histologic grade, subtypes, chemotherapy response, and local treatment showed differences. Event-free survival (EFS) and overall survival (OS) demonstrated no significant difference between the pCR and MRD groups. In the multivariate analysis, pCR status was the only significant factor in EFS, and no statistical difference was noted between the pCR and MRD groups. However, clinical stage, pCR status, and subtype significantly affected the OS. MRD showed favorable outcomes in terms of both EFS and OS in all subtypes, except for those with triple-negative breast cancer (TNBC). Conclusion: Patients with MRD showed outcomes comparable to those of patients who achieved pCR and may be candidates for de-escalation of post-NAC treatment, except for those with a TNBC subtype.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-
dc.relation.isPartOfANNALS OF SURGICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / therapeutic use-
dc.subject.MESHBreast Neoplasms* / pathology-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHNeoplasm, Residual / pathology-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTriple Negative Breast Neoplasms* / pathology-
dc.titleDistinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorJieon Go-
dc.contributor.googleauthorJee Hyun Ahn-
dc.contributor.googleauthorJung Min Park-
dc.contributor.googleauthorSoon Bo Choi-
dc.contributor.googleauthorJee Ye Kim-
dc.contributor.googleauthorHyung Seok Park-
dc.contributor.googleauthorSeung Il Kim-
dc.contributor.googleauthorByeong-Woo Park-
dc.contributor.googleauthorSeho Park-
dc.identifier.doi10.1245/s10434-023-13938-x-
dc.contributor.localIdA00658-
dc.contributor.localIdA00984-
dc.contributor.localIdA01475-
dc.contributor.localIdA01524-
dc.contributor.localIdA06148-
dc.contributor.localIdA01753-
dc.contributor.localIdA06150-
dc.relation.journalcodeJ00179-
dc.identifier.eissn1534-4681-
dc.identifier.pmid37537485-
dc.identifier.urlhttps://link.springer.com/article/10.1245/s10434-023-13938-x-
dc.subject.keywordBreast cancer-
dc.subject.keywordDe-escalation-
dc.subject.keywordMinimal residual disease-
dc.subject.keywordNeoadjuvant chemotherapy-
dc.subject.keywordPathologic complete response-
dc.subject.keywordResidual cancer burden-
dc.contributor.alternativeNameKim, Seung Il-
dc.contributor.affiliatedAuthor김승일-
dc.contributor.affiliatedAuthor김지예-
dc.contributor.affiliatedAuthor박병우-
dc.contributor.affiliatedAuthor박세호-
dc.contributor.affiliatedAuthor박정민-
dc.contributor.affiliatedAuthor박형석-
dc.contributor.affiliatedAuthor안지현-
dc.citation.volume30-
dc.citation.number12-
dc.citation.startPage7060-
dc.citation.endPage7068-
dc.identifier.bibliographicCitationANNALS OF SURGICAL ONCOLOGY, Vol.30(12) : 7060-7068, 2023-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.